摘要
目的探讨碳酸锂分别联合丙戊酸钠和利培酮治疗急性躁狂发作的疗效和安全性。方法将94例急性躁狂发作患者随机分为两组,碳酸锂联合丙戊酸钠47例,碳酸锂联合利培酮47例,疗程均为8周。分别于治疗前及治疗后的第2、4、8周,采用躁狂量表(BRMS)评定临床疗效,治疗时出现的症状量表(TESS)评定安全性。结果碳酸锂分别联合戊酸钠和利培酮治疗急性躁狂发作的疗效相当(P>0.05),但前者起效快、不良反应少(P<0.05)。结论碳酸锂联合丙戊酸钠治疗急性躁狂发作起效快、疗效显著、不良反应少,安全性高。
Objective To explore the safety and efficiancy of combination lithium carbonate with sodium valproate vs risperidone.Methods 94 patients with acute manic episode were randomly assigned to valproate group and risperidone group,47 patients received combination of lithium carbonate and sodium valproate,while another group were treated with lithium carbonate and risperidone.The efficiancy was assessed by scores of Beck-Rafaelsen mania Rating Scale（BRMS）,adverse reactions were evaluated by Treatment Emergent Symptom Scale（TESS）at baseline and the second,forth,eighth week of treatment.Results At baseline,the first and eighth week patients scores were not significantly different（P〉0.05）,However,while at the second and fouth week of treatment patients scores of combination of lithium carbonate and sodium valproate were lower than those of combination of lithium carbonate and risperidone（P〈0.05）.All the time,adverse reactions of the first group were significantly lower than that of the second group.Conclusion The combination of lithium carbonate and sodium valproate have more early effect and safety than that of lithium carbonate and risperidone.
出处
《四川精神卫生》
2011年第2期83-85,共3页
Sichuan Mental Health
关键词
急性躁狂发作
碳酸锂
丙戊酸钠
利培酮
Acute manic episode Lithium carbonate Sodium valproate Risperidone.
